

## Research Interests

### Molecular mechanisms of G protein-coupled receptor signalling

Georgoussi's laboratory studies the molecular mechanisms by which cellular signaling regulates cell function and how signaling mechanisms affect human health. Specifically, we study G-protein signaling cascades and their dynamic regulation by activated receptors, RGS (Regulator of G-protein Signaling) proteins and other factors. We have a long-standing interest in the family opioid receptors ( $\mu$ ,  $\delta$  and  $\kappa$ ), which are implicated in pain mechanisms and addiction processes as well as in neuronal cell survival and differentiation.

### Dissection of opioid receptor signaling

We are exploring the ability of RGS proteins to attenuate GPCR signaling. In this respect, we have demonstrated that RGS4 and RGS2 proteins interact with  $\delta$ -  $\mu$ - and  $\kappa$ -opioid receptors to confer selectivity for Gi/o proteins (Figure 1) and thus modulate negatively their signaling by affecting adenylyl cyclase activity, MAP kinase phosphorylation and agonist induced internalization in a differential manner for each receptor subtype ( [Georgoussi et al., 2006](#) ; [Leontiadis et al., 2009](#)

; Papakonstantinou et al., 2015;

<http://en.wikipedia.org/wiki/CCG-4986>

Parallel studies have shown that spinophilin, a ubiquitous multidomain scaffold protein, which occurs abundantly in dendritic spines, interacts also with the  $\mu$ - and  $\delta$ -opioid receptors and forms a signaling complex with Gi/o and RGS4 proteins to positively regulate  $\mu$ - and  $\delta$ -opioid receptor signaling ( [Furla et al., 2012](#) ; [Georgoussi et al., 2012](#) ). Current studies focusing on neuronal cells attempt to establish whether spinophilin i) is regulated by opioid administration and ii) is implicated in neuronal development and nervous system disorders in RGS4


-/-

knockout animals.

□

Figure 1

Putative models of  $\delta$ -,  $\kappa$ - and  $\mu$ -opioid receptor - RGS4 - G protein coupling



**Functional analysis of genes whose expression is altered by opioid administration.**

A landmark of our research has been the finding that members of the Signal Transducers and Activators of Transcription (STATs) such as STAT5A/B directly interact with the  $\delta$ - and  $\mu$ -opioid receptors and are phosphorylated in response to opioids in neuronal cells ( [Mazar akou and Georgoussi, 2005](#) )



;  
[Georgoussi et al., 2012](#)  
[Georganta et al., 2010](#)

;  
[Georgoussi et al., 2012](#)

). This interaction is mediated by a multi-component signalling complex – a signalosome - a platform composed of STAT5B, c-Src kinase and selective Gai/o, G $\beta$  subunits (Figure 2),

which assemble on using the C-terminus of the  $\delta$ -opioid receptor .

Figure 2



A putative signalling pathway of the  $\delta$ -opioid receptor-phosphorylated-STAT5B-G protein complex, implicated in neuronal differentiation. Confocal images of cells expressing the  $\delta$ -OR

(green) indicate an increased neurite length after DSLET administration (Tuj-1-labelling yellow) ([Mazarakou and Georgoussi 2005](#))

;

[Georganta et al., 2010](#)

),

[Georganta et al., 2013](#)

)

This dynamic protein complex is implicated in cell survival, neurite outgrowth and differentiation following opioid administration to Neuro-2A cells and primary neuronal cortical cultures ([Georganta et al., 2010](#))

;


[Georganta et al., 2013](#)

; Pallaki et al., manuscript submitted).

Based on such findings we are currently dissecting in more detail the role of STAT5B and RGS4 in neurogenesis in the context of opioid receptor-mediated function using RGS4<sup>-/-</sup> mice. Our studies on neuronal stem cells from such mice, suggest that the interplay between G and RGS4 proteins with STAT5 is important for neuronal differentiation and outgrowth (Figure 3). Our current goal is to define whether RGS4-STAT5B coupling is modulated by opioids and constitutes an underlying factor for neuronal and neuroinflammatory diseases.

Figure 3.

### **RGS proteins alter neurite outgrowth mediated by the activated $\delta$ -OR**



## New therapeutical agents: Identification and pharmacological characterization

As a member of the EU- [network](#) “ [NORMOLIFE](#) ” we have characterized the pharmacological properties of new opioid compounds with potent *in vivo*

analgesic effects using cell based assays. (

[EKT](#)

, [Pasquinucci et al., 2010](#)

; [Vandormael et al., 2011](#)

; [Pasquinucci et al., 2012](#)

). Finally, in collaboration with the laboratory of

[Insect Molecular Genetics & Biotechnology](#)

, we develop reporter gene and/or second messenger cell-based high throughput screening

platforms to monitor cellular responses for identification of lead compounds with relevant

pharmaceutical potential in plant extracts. (Swewers et al. 2005; Douris et al. 2006; Tsitoura et al. 2010; Greek Patent office 20040100397)